Analyst Upgrade AMGN
2 weeks ago.
William Blair reiterates a Buy rating on undervalued biotech company Amgen Inc (AMGN) despite setbacks, with optimism for upcoming FORTITUDE-102 trial.
Earnings News LLY NVO VKTX PFE AMGN
1 month ago.
Eli Lilly (LLY) Q2 2025 earnings report beats expectations, but stock plunges 14.14% due to disappointing results for oral weight-loss pill, impacting future growth outlook.